The US Food and Drug Administration (FDA) has approved new Covid-19 vaccines. These updated vaccines have received emergency use authorization. They are designed to offer better protection against the currently circulating variants.
On Thursday, the FDA announced that these vaccines target the Omicron variant KP.2 strain. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, emphasized the importance of these updates. “Given waning immunity of the population from previous exposure to the virus and from prior vaccination, we strongly encourage those who are eligible to consider receiving an updated Covid-19 vaccine to provide better protection against currently circulating variants,” Marks said.
Also Read: Bangladesh Government Revokes Diplomatic Passports Of Ex-PM Hasina
The updated mRNA vaccines include Comirnaty and Spikevax. These vaccines are approved for individuals 12 years of age and older. Additionally, the Moderna Covid-19 Vaccine and the Pfizer-BioNTech Covid-19 Vaccine are authorized for emergency use. These vaccines are available for children aged 6 months through 11 years.
Transitioning to the practical implications, these updated vaccines aim to address the reduced immunity from past infections and vaccinations. They provide a more tailored response to current virus strains. This step is crucial for maintaining effective protection against Covid-19.
In summary, the FDA’s approval of these updated vaccines represents a significant move in the fight against Covid-19. By targeting the latest variants, these vaccines are expected to improve overall protection for both adults and children.